Predicting future heart problems in young adults with premature coronary artery disease (MAP-CHD)
Official title: Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial
Run by China National Center for Cardiovascular Diseases · NCT07004452 · Data updated 2026-11-12
This project will follow Chinese adults under 45 with premature coronary artery disease to see if clinical features and blood tests can predict future adverse heart events.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | China National Center for Cardiovascular Diseases Government |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | March 31, 2025 |
| Main results expected | July 2027 |
| Study ends | July 2027 |
| Registry record updated | June 4, 2025 |
| Trial ID | NCT07004452 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Chinese adults 18–45 with at least 50% coronary stenosis on angiography who are clinically stable if enrolled after ACS or PCI and can give informed consent.
✕Probably not a fit
Patients unlikely to benefit include heart transplant recipients, those with life-limiting comorbidities (life expectancy <1 year), or individuals unable to complete follow-up.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
MAP-CHD is an observational cohort that enrolls patients aged 18–45 with angiographically confirmed coronary artery disease and follows them for two years. Participants will have a blood draw at one year and routine outpatient or telephone follow-up at other timepoints to capture clinical outcomes. The study will combine clinical, laboratory, and phenotypic data to build a risk prediction model for adverse events and compare prognosis across disease phenotypes. No experimental treatments are given; the aim is to generate tools to stratify risk in this younger patient group.
Why it matters
Potential benefit: If successful, the model could help identify young patients at high risk of future heart problems so clinicians can tailor monitoring and preventive care.
How similar studies have gone: Existing risk models for coronary disease exist but few focus specifically on Chinese patients under 45, so this multimodal prediction approach is relatively novel for this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-45 years; * Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography; * For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment; * Voluntary participation with signed informed consent. Exclusion Criteria: * Heart transplant recipients; * Severe systemic comorbidities with life expectancy \<1 year; * Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period; * Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).
Where it's running
-
FuWai Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Jingjing Xu
- Email: 335418449@qq.com
- Phone: 86 134-260-50924
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-guided post-discharge care for premature coronary artery disease
This trial will test whether an AI-powered app and stratified management system can lower deaths, heart attacks, strokes, and rehospitalizations and improve risk-factor control in adults aged 18–45 with premature coronary artery disease.
-
Evaluating VERVE-102 for lowering cholesterol in specific heart disease patients
This study is testing a new gene-editing treatment called VERVE-102 to see if it can lower cholesterol levels in people with certain heart conditions.
-
Conscious Sedation vs General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fibrillation
This trial tests whether local anesthesia with conscious sedation can match general anesthesia for pulsed field ablation in adults with paroxysmal atrial fibrillation.
-
Biomarkers to predict CSA-AKI risk before heart surgery
This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.
-
Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock
This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.
-
QFR-Guided Heart Revascularization Quality Registry in CAD
This registry tests whether using quantitative flow ratio (QFR) to guide coronary revascularization decisions across many centers can standardize quality in patients with coronary artery disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.